Twenty-five states are backing the federal government in litigation before two federal appeals courts over drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.
…Category: News Alert
News Alert
Merck Extends its Conditions on 340B Pricing Involving Contract Pharmacies to Health Centers
Drug manufacturer Merck today extended its restrictions on 340B pricing involving contract pharmacies to community health centers.
News Alert
HRSA Refers Boehringer Ingelheim to HHS Inspector General over its 340B Contract Pharmacy Policy
The U.S. Health Resources and Services Administration (HRSA) today turned the screws tighter on Boehringer Ingelheim (BI) over its “continued failure to provide the 340B price to covered entities utilizing contract pharmacies.”
…Drug manufacturer Johnson & Johnson this afternoon announced conditions on 340B sales on 29 products—including several of its top-selling drugs—when hospitals use contract pharmacies.
The National Association of Community Health Centers (NACHC) told drug manufacturer Gilead this morning its new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments are “unconscionable,” “appalling,” “wrongheaded,” and “the latest example of corporate greed from
…News Alert
HRSA Starts Contacting Hospitals Forced Out of 340B During Pandemic About Possible Reinstatement
The U.S. Health Resources and Services Administration (HRSA) this morning began contacting hospitals forced to leave the 340B program during the COVID-19 pandemic about possible reinstatement to 340B under a new federal law.
…News Alert
Gilead Announces 340B Contract Pharmacy Restrictions that Apply to Hospital and Grantee Entities
Gilead late yesterday imposed conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies.
The U.S. Senate last night passed a $1.5 trillion federal appropriations bill with language to help some hospitals forced out of the 340B program during the COVID-19 pandemic.
…Legislation addressing hospitals’ loss of eligibility for 340B drug discounts due to COVID-19-related changes in payer mix could reach President Biden before Friday at midnight.
…*Sign up for news summaries and alerts from 340B Report